i-Series Plus integrated HPLCSignificantly improved analytical productivity with automated pretreatment operations
The i-Series Plus, designed for covering conventional to ultra-fast LC applications, consists of the compact HPLC Prominence-i and UHPLC system Nexera-i. High speed analysis, simplified method transfer, minimized environmental impact and easy maintenance are just a few of the many new features of this product range
Shimadzu’s i-Series Plus expands the product line and improves performance and user-friendliness. With i-Series Plus, pretreatment operations have been automated, such as the processes to dilute samples and add reagents. This results in better reproducibility and measurement accuracy by minimizing human error, to ensure reliable data in the analysis of pharmaceuticals and foods. i-Series Plus also offers new features that satisfy data integrity requirements of the pharmaceutical industry. The i-Series Plus consists of the compact HPLC Prominence-i and UHPLC system Nexera-i.
For more information please visit: www.shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
